Russian state needs additional funds to ensure domestic generic production

The Russian Ministry of Health has called on domestic drugmakers to accelerate efforts for the development and production of cheaper analogues of expensive drugs, particularly those that are used for the treatment of socially significant diseases, according to recent statements made by Sergey Glagolev, deputy head of the Ministry.

Sergey Glagolev comments: “We would like to see an increase in the share of expensive, perhaps second-in-class, but more affordable drugs for socially significant diseases. I'm talking about 14 high-cost nosologies program (a state program in Russia, which involves public procurements of the most expensive drugs), orphan diseases, as well as such serious diseases as oncology, cardiac and infectious diseases.”

According to the deputy minister, price regulation should also be improved, primarily in the segment of high-priced drugs, while there is a need to create conditions for more active cooperation among the Russian pharmaceutical companies.